I believe the company has turned the corner and is operating with a clear focus and directive compared to 2 years ago. No more dealing with Chinese government and AMR-oo1 which will be the big revenue generator has fully enrolled P2. PCT is generating revenues that can support the company research along with the grants and partnerships they have in place.
Valuation should be heading north rapidly once it takes off.
Yup, the message is very clear, that NBS is undervalued and cheap at the present prices. Compare it with the 2 other stocks mentioned in the article as fair value and overvalued, you will then realize the potential of NBS.